CCM
ACHL

Corsair Capital Management’s Achilles Therapeutics ACHL Stock Holding History

Corsair Capital Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$20.4K – 148
2024
Q3 		$20.4K Buy
+20,000
New +$16K ﹤0.01% 117

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Corsair Capital Management's ACHL Position: Q4 2024 in Review

Corsair Capital Management sold out of Achilles Therapeutics (ACHL) in Q4 2024, closing a stake of 20,000 shares — an estimated $20.4K sold.

Corsair Capital Management first reported a position in ACHL in Q3 2024 and held it in 1 quarter. The position peaked at $20.4K in Q3 2024. 21 funds tracked by Wall St. Rank hold ACHL as of Q4 2024.

  • Corsair Capital Management reported no remaining Achilles Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Corsair Capital Management sold 20,000 Achilles Therapeutics shares in Q4 2024, an estimated $20.4K.
  • Corsair Capital Management first reported a position in Achilles Therapeutics in Q3 2024 and held it in 1 quarter.
  • Corsair Capital Management's Achilles Therapeutics position peaked at $20.4K in Q3 2024.
  • 21 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2024.

Based on Corsair Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.